.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Fish and Richardson
US Department of Justice
Argus Health
QuintilesIMS
UBS
Citi
Federal Trade Commission
Boehringer Ingelheim
AstraZeneca

Generated: November 19, 2017

DrugPatentWatch Database Preview

Magna Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for MAGNA PHARMS, and when can generic versions of MAGNA PHARMS drugs launch?

MAGNA PHARMS has one approved drug.

There are two US patents protecting MAGNA PHARMS drugs.

There are eighty-eight patent family members on MAGNA PHARMS drugs in ten countries and five supplementary protection certificates in four countries.

Summary for Magna Pharms

International Patents:88
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Magna Pharms
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL022196-001Dec 19, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
Magna Pharms
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL022196-001Dec 19, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Magna Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Magna Pharms
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL022196-001Dec 19, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expirations for MAGNA PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Magna Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,676,931 Buccal, polar and non-polar spray or capsule► Subscribe
6,998,110Buccal, polar and non-polar spray or capsule► Subscribe
6,977,070 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system► Subscribe
6,969,508 Buccal, polar and non-polar spray or capsule containing drugs for treating pain► Subscribe
9,078,816Buccal, polar and non-polar spray containing ondansetron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Magna Pharms Drugs

Country Document Number Estimated Expiration
European Patent Office2283813► Subscribe
World Intellectual Property Organization (WIPO)2005032520► Subscribe
Canada2554954► Subscribe
South Korea20060090997► Subscribe
World Intellectual Property Organization (WIPO)2005032519► Subscribe
Japan2006505569► Subscribe
World Intellectual Property Organization (WIPO)2004019909► Subscribe
Australia2003270016► Subscribe
World Intellectual Property Organization (WIPO)2004019911► Subscribe
World Intellectual Property Organization (WIPO)2005032517► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Magna Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000006Germany► SubscribePRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
2015 00004Denmark► SubscribePRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
636Luxembourg► SubscribePRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
00714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
0714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Julphar
Covington
Federal Trade Commission
UBS
Moodys
Medtronic
Queensland Health
Novartis
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot